(Q37499437)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Quadrivalent meningococcal conjugate vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2

Andrew J Pollard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Nancy E Messonier

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

27 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

27 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

B30-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Understanding vaccine safety information from the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Issues surrounding standardization of meningococcal group W135 serology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

Use of meningococcal vaccines in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

The Meningitis Vaccine Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.003

10.1016/J.VACCINE.2009.05.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19477560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference